StockWatch
·
HLE GLASCOAT LTD · QQ2 FY-2027 · THE CALL

Record order book masks Q2 revenue stall, guidance slipped

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsHLEGLASHLE Glascoat Ltd09 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade C

Prior FY27 ₹2,000+ Cr target missed; now guided FY28. H1 margins (9.5%) below historical 15%+ levels.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Strong order backlog (₹1,087 Cr) and record EUR20.56M tunnel order signal multi-year growth visibility. However, Q2 revenue flat YoY (-1.2%), H1 EBITDA margin 9.5% vs 15% target, and FY27 guidance slipped from ₹2,000+ Cr to ₹900 Cr (cut). Risk: execution on ₹1,087 Cr backlog over 3–5 years while managing working capital (102 days) and margin recovery in integrating units (Omeras, THALETEC).

₹346.7 Cr

Revenue · −1.2% YoY

₹16 Cr

Reported PAT · +14.8% YoY

Compressing

Margins · vs guidance: Overstated

Did the claims hold up?

Management's claims vs. the numbers

Positive momentum confirmed from Q1 continuation

OVERSTATED

Q2 up 15.3% QoQ but down 1.2% YoY; H1 margins 9.5% vs 15% target

Order book ₹1,087 Cr crossed ₹1,000 milestone, 51% YoY growth

MET

Confirmed; backlog grew from ₹662 Cr (June '26) to ₹1,087 Cr (Sept '26)

Omeras achieved breakeven in H1 FY27

MET

Confirmed; H1 revenue EUR8.5M, EBITDA breakeven; Q4 FY26 was loss

FY28 revenue ₹2,000 Cr on track

MISS

FY27 guidance slipped to ₹900 Cr (₹647 H1 + ₹260–280 H2); prior FY27 target was exceed ₹2,000 Cr

THALETEC contributing 22% of glass-lined revenue in India

MET

Confirmed; product mix shifting to premium offerings, margin benefit forthcoming

Earnings quality

What changed since the last call

Deltas vs. the prior call

FY27 revenue target slipped to FY28

Downgrade

Prior call: exceed ₹2,000 Cr for FY27. Now: FY27 ~₹900 Cr (₹647 H1 + ₹260–280 H2 guidance), FY28 ₹2,000 Cr. One-year delay, but magnitude confirmed as milestone.

Order book crossed ₹1,000 Cr milestone

Upgrade

Sept 30: ₹1,087 Cr vs ₹662 Cr (June '26, assumed prior Q1 ending). Growth of ₹425 Cr inflow. Visibility now extends 3–5 years out.

Omeras achieved EBITDA breakeven

Upgrade

Q4 FY26 was loss; H1 FY27 breakeven at EUR8.5M revenue. Path to profitability now clear; margin initially 12–15% target.

Working capital cycle extended

Downgrade

WC days 80 (FY26) → 102 (Sept '26). Management acknowledged need for DSO/inventory discipline. Cash conversion cycle deteriorating.

GLE segment margin compression

Downgrade

Prior peak 18%+; now struggling. H1 FY27 GLE revenue ₹195.4 Cr (+24.2% YoY but margins not disclosed; implied single-digit to low-teens from blended 9.5%). Competitive intensity cited as driver.

The Q&A

Analysts pressed hard on Omeras and GLE weakness (Ankit Gupta, Ajay Surya). Management clarified execution timelines, acknowledged customer acceptance delays, but deferred specific margin recovery timeline. Held firm on ₹2,000 Cr FY28 target and 15% EBITDA. Q&A had 7 detailed questions; 5 answered substantively, 2 partially dodged (GLE path forward, exact Omeras margin ramp).

The exchanges that mattered

Demand geography and order composition — Aviral Sharma, Finvenue Growth Fund

Answered

India pharma & chemicals strong. Europe subdued but US robust. EUR20.56M tunnel order for Germany–Denmark delivery over 3–3.5 years. Omeras targeting >EUR25M revenue once fully ramped; heavy engineering segment potential ₹1,500–2,000+ Cr.

Domestic GLE weakness vs pharma outperformance — Ankit Gupta, Bamboo Capital

Partial

Execution delay 4–7 months typical. Q1 was soft, Q2 better. GLE margins at high single-digit now; pricing power limited due to competitive intensity. THALETEC adoption helping; expect improvement in Q3–Q4.

Omeras operational performance and trajectory — Ajay Surya, Niveshaay

Answered

H1 FY27 breakeven achieved. Chief Operations Officer hired from US multinational. CFO recently boarded. Expect profitability inflection once 12–18 month transition complete. Omeras margin contribution will exceed HLE standalone.

EBITDA margin path and FY28 target credibility — Ajay Surya, Niveshaay

Partial

GLE can do 12–14% range. Kinam 16% sustainable. F&D 16% potential. Omeras initially 12–15%, then 22% at scale. Heavy engineering 15–22% at maturity. Weighted blended achieves 15% if revenue mix and execution on track.

Kinaam business potential and order execution — Ankit Gupta, Bamboo Capital

Answered

Oil & gas order is lumpy, 12–18 months to first execution, then ongoing over years. Core Kinam business growing steadily, 16% sustainable. Kinam heavy engineering plant (Anand) will be new growth driver with track record orders.

Competitive intensity, pricing power, GLE segment — Ajay Surya, Niveshaay

Partial

Competitive intensity easing as market demand picks up. THALETEC positioned as premium offering; pricing power improving. GLE benefiting as customers shift to higher-value products. Positioning as technology solution provider, not just equipment manufacturer.

FY28 ₹2,000 Cr revenue target confidence — Ajit Sethi, Eiko Quantum Solutions

Answered

Yes, on track. FY27 expected ₹900 Cr, FY28 ₹2,000 Cr. Mix of existing products (GLE, Kinam growth), new (Omeras scale, THALETEC adoption), new plant heavy engineering (5–7% add). Delivery over 3–5 years provides visibility.

Guidance

Forward guidance and management's confidence

FY27 revenue ~₹900 Cr (₹647 H1 + ₹260–280 H2)

High

H1 delivered; H2 visibility limited to Q3–Q4 execution. Order conversion expected within 4–7 months.

FY28 revenue ₹2,000 Cr (100% growth YoY)

Medium

Driven by existing product growth (GLE, Kinam, FDO), new product ramp (Omeras, THALETEC), heavy engineering entry. Execution risk on capex completion and market adoption.

EBITDA margin 15% by FY28 (vs H1 FY27 9.5%)

Medium

Requires GLE 12–14%, Kinam 16%, F&D 16%, Omeras 12–15% ramping to 22%, heavy engineering 15–22%. Mix and pricing discipline needed.

NPM target not explicitly stated; implied 8–10% at FY28

Low

Current NPM 4.6%; interest and depreciation to remain headwinds as debt and capex climb.

Heavy engineering plant capex (Anand site, near completion)

Medium

Plant expected operational by Q4 FY27 or Q1 FY28. Initial focus on large equipment (100–150 ton units). Ramp-up gradual over 2–3 years.

Risks the call surfaced

Ranked by how much they should concern a holder

Execution on order backlog

High

₹1,087 Cr backlog is 3–5 year visibility, but Q2 revenue flat YoY despite ₹775 Cr inflow. Supply chain delays and customer acceptance postponements can compress FY27–FY28 realization.

Margin recovery credibility

High

H1 EBITDA margin 9.5% vs 15% FY28 target requires 560 bps improvement. GLE margins at high single-digit due to competitive intensity; Omeras and THALETEC still at breakeven/early ramp. Mix shift to new lower-margin products delays recovery.

Working capital deterioration

High

WC days expanded 80 → 102 days as order book inflated from ₹662 to ₹1,087 Cr. Cash conversion cycle deteriorating; management acknowledged need for tighter DSO and inventory discipline. Risk of free cash flow squeeze if not managed.

GLE segment profitability pressure

Medium

India GLE business facing competitive intensity from equipment manufacturers filling capacity post-capex slump. Pricing bids down; realized ASPs under pressure. GLE margin historically 18%+; now implied single-digit. THALETEC product mix (22% of GL) helping, but not enough to offset.

Omeras integration and profitability scaling

Medium

Omeras acquired ~1 year ago; achieved H1 FY27 breakeven only. Prior Q4 FY26 was loss. Long ramp to targeted 22% EBITDA margin assumed. New COO and CFO recently onboarded. Management capability and execution risk remains.

FY27 guidance miss; credibility erosion

Medium

Prior FY27 guidance (from FY26 call) was to exceed ₹2,000 Cr. Current expectation ~₹900 Cr (₹647 H1 + ₹260–280 H2). Significant miss. Now guidance pushed to FY28 ₹2,000 Cr with confidence eroded.

Management

Score 6/10. Detailed and transparent on operations (segment split, order book, acquisition updates). Cautious on forward guidance specifics; defers quarterly breakdown. Acknowledges risks (geopolitical, execution lag, WC) but sometimes hedges exact numbers (margin ramp path). Mixed track record. Prior FY27 ₹2,000+ Cr guidance missed; Omeras integration took longer (breakeven only in H1 after Q4 loss). But new plant (Anand) on track, order inflows strong, and large customer wins (EUR20.56M) suggest improving operational capability.

What to watch next
  • 1 · Q3–Q4 FY27

    Execution on ₹425 Cr order inflow; revenue ramp to ₹260–280 Cr H2

  • 2 · H2 FY27–H1 FY28

    Heavy engineering plant near Anand operational; THALETEC volume adoption in India

  • 3 · FY28

    EUR20.56M tunnel panel project supplies begin (3–3.5 year delivery); Omeras profitable scale

Risk: execution on ₹1,087 Cr backlog over 3–5 years while managing working capital (102 days) and margin recovery in integrating units (Omeras, THALETEC).

Informational and educational content only. Not investment advice.